Articles by Ronald A. Rader
Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs
Manufacturing capacity for both cell therapies and gene therapy viral vectors remains in short supply. From BioPlan Associates, Inc.'s new survey of biopharmaceutical manufacturing professionals, there is a current and worsening capacity crunch. The industry continues to demand innovative solutions from its suppliers in key areas that can be slow to develop.
Changing Perceptions On Bioprocess Intensification, Continuous Processing
Process intensification and continuous bioprocessing are concepts with inconsistent definitions. What's included often varies greatly and, in some ways, has become more about aspirational goal-setting than actual innovation adoption. Here, BioPlan Associates assesses the changing perspectives of 122 bioprocess decision-makers.
Bioprocessing Year In Review: 11 Key Trends Accelerated By COVID-19
Despite the morbidity, deaths, and terrible societal disruptions associated with the COVID-19 pandemic, 2020 will have created something of a positive outcome for the bioprocessing sector.
COVID-19’s Impact On Bioprocessing: Insights From Industry Leaders
We interviewed 26 biopharma senior executives regarding how they are handling the crisis and its long-term impact on their operations. We found the pandemic has begun to catalyze and accelerate a number of significant changes, including many preexisting trends.
Biosimilar Pipeline Experiencing 12% Annual Growth: A Progress Update
This article compares aspects of the biosimilar development pipeline and related market evolution since 2013, including what has and hasn’t changed.
Biosimilars Pipeline Shows Remarkable, Sustained Growth
The biosimilars pipeline is progressing rapidly and continues to grow, with more products and more organizations involved. This article reviews the current biosimilars development pipeline and progress.
Top Trends In The Biopharmaceutical Industry And Bioprocessing For 2019
This article presents trends and findings from a survey and study of 222 responsible individuals at biopharmaceutical manufacturers and CMOs in 22 countries, as well as over 130 direct suppliers of materials, services, and equipment to this industry.
New Microbiological Methods In Bioprocessing
Testing for evidence of microbial contamination in bioprocessing has a long history — and can be expensive, slow, and burdensome. So suppliers, testing facilities, and regulators have been seeking improvements.
Overcoming The Manufacturing Hurdles Of Cell & Gene Therapy
A number of innovative cellular and gene therapies are in development, and R&D and investments in these fields are rapidly growing. Although the number of approvals and markets remain very small — negligible by the standards of the mainstream (bio)pharmaceutical industry — this is likely to change as the first clinical trials are successfully concluded.
Biosimilars Pipeline Analysis: Many Products, More Competition Coming
Our discussion of biosimilars in this article will center on developed-market GMP biosimilars. In the European market alone, biosimilars already are a multibillion-dollar business, and one that is rapidly growing.